Jackson Square Capital LLC Sells 4,712 Shares of Stryker Corporation $SYK

Key Points

• Jackson Square Capital LLC cut its Stryker stake by 57.9% in Q4, selling 4,712 shares and leaving the fund with 3,423 shares worth $1.203M; meanwhile director Ronda E. Stryker sold 250,000 shares at an average $362.92 (~$90.7M), reducing her ownership by 9.23%.
• Stryker topped Q4 expectations, reporting EPS of $4.47 (vs. $4.40 est.) and revenue of $7.17B (up 11.4% year‑over‑year), and analysts are largely positive (14 Buys, 5 Holds) with an average target of $425.56.
• The company declared a quarterly dividend of $0.88 (annualized $3.52) with an ex‑dividend/record date of March 31 and a payment date of April 30, implying a yield of about 1.0%.

Jackson Square Capital LLC lessened its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 57.9% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,423 shares of the medical technology company's stock after selling 4,712 shares during the quarter. Jackson Square Capital LLC's holdings in Stryker were worth $1,203,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Clayton Financial Group LLC bought a new position in shares of Stryker during the 3rd quarter worth $26,000. United Financial Planning Group LLC bought a new position in shares of Stryker during the 3rd quarter worth $27,000. Strive Asset Management LLC bought a new position in shares of Stryker during the 3rd quarter worth $30,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Stryker during the 3rd quarter worth $34,000. Finally, Lavaca Capital LLC bought a new position in shares of Stryker during the 2nd quarter worth $40,000. Institutional investors own 77.09% of the company's stock.

Stryker Trading Up 2.3%

Stryker stock opened at $339.85 on Thursday. The stock has a 50-day moving average of $355.78 and a two-hundred day moving average of $360.97. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. Stryker Corporation has a one year low of $319.32 and a one year high of $404.87. The stock has a market cap of $130.16 billion, a PE ratio of 40.46, a price-to-earnings-growth ratio of 1.94 and a beta of 0.92.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating analysts' consensus estimates of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The company had revenue of $7.17 billion during the quarter, compared to analysts' expectations of $7.12 billion. During the same period last year, the business posted $4.01 earnings per share. The firm's revenue was up 11.4% compared to the same quarter last year. On average, research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker's dividend payout ratio (DPR) is 41.90%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 5.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on SYK. Raymond James Financial raised Stryker from a "market perform" rating to an "outperform" rating and set a $418.00 price target on the stock in a research report on Tuesday, January 6th. Piper Sandler reissued an "overweight" rating on shares of Stryker in a research report on Tuesday, January 27th. Weiss Ratings reissued a "hold (c+)" rating on shares of Stryker in a research report on Monday, December 22nd. Needham & Company LLC increased their price target on Stryker from $448.00 to $454.00 and gave the stock a "buy" rating in a research report on Friday, January 30th. Finally, Citizens Jmp raised Stryker from a "market perform" rating to an "outperform" rating and set a $440.00 price target on the stock in a research report on Friday, December 19th. Fourteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $425.56.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.